Baxter to Acquire Hillrom for ~$10.5B
Shots:
- Baxter to acquire Hillrom for $156.00/ share in cash making a total equity value of ~$10.5B representing a premium of 26% to the stock’s closing price of $124 and a total enterprise value of ~ $12.4B- including the assumption of debt. The acquisition is expected to be closed in early 2022
- The acquisition will expand access to Hillrom’s portfolio globally and accelerate the companies’ expansion into digital and connected care solutions at home or in other care settings
- Baxter to get a broader array of medical products and services to patients and clinicians across the continuum of care. The companies expect about $250M in annual cost synergies over the next three yrs.
| Ref: Businesswire | Image: Baxter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com